Multiple Mechanisms of HIV-1 resistance to PGT135 in Chinese Subtype B' Slow Progressor

Shasha Sun^a, Sen Zou^a, Yuanyuan Hu^a, Ying Liu^a, Li Ren^a, Yanling Hao^a, Xintao Hu^{a,b}, Yuhua Ruan^a,
Liyang Ma^a, Yiming Shao^a, Kunxue Hong^{a#}

^aState Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD
Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.

^bHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer
Institute, Frederick, MD, United States.

Running Head: Multiple Mechanisms of HIV-1 resistance to PGT135

#Address correspondence to Dr. Kunxue Hong, Email: hongkx@chinaaids.cn.

Word count: abstract: 212; text: 5229.

18 **ABSTRACT**

19 In our study, we describe a slow progressor CBJC515 from whom we constructed pseudoviruses
20 expressing autologous Env. We surprisingly found all the pseudoviruses were resistant to PGT135. By
21 making site-directed mutations and chimeric Env constructs, we found the early 05 strains escaped from
22 PGT135 by losing the N332 glycan site, while the later 06 and 08 strains may escape with the retention
23 of key epitopes through the change of V1/V4/C2 region or by N398/N611 glycan, which was selected as
24 unique N-glycosylation site of CBJC515 compared with CBJC437 whose viruses were also harboring
25 key epitopes but sensitive to PGT135. These findings provide insights into how HIV-1 can escape from
26 N332-directed broadly neutralizing antibody (bNAb) responses without changing the epitope itself, and
27 these ways may be useful to prolong the exposures of bNAb epitopes and contribute to bNAb
28 development. Furthermore, our chimeric experiments also allowed us to explore the co-evolution and
29 retention of functionality among regions. We confirmed that the V1V2 region has a wide range of
30 effectiveness in interfering with the function of envelope protein and the V3 region can promote protein
31 function recovery and buffer the harmful polymorphisms in the other regions contributing to the Env
32 antigenic diversity. These results may provide some clues for the design of vaccines against HIV-1
33 strains.

34 **IMPORTANCE**

35 Our findings of mechanisms escaping from PGT135 verified the extensive role of long V1 region
36 in mediating escape from V3-bNAbs. In addition, we also found multiple additional ways suggested that
37 extreme variation may be needed by HIV-1 to escape from PGT135 without changing the epitope itself.

Although the V3-glycan bNAb responses are among the most promising vaccine targets, as they are commonly elicited during infection, our findings indicated there may be additional difficulties to be taken into account in immunogen design, such as the consideration of other regions and some glycosylation sites affecting the mask of key epitopes, as well as the selection pressure that may be required by other bNAbs. Our chimeric experiment also highlighted the key role of V3 region in contributing to the maintenance of Env diversity by buffering deleterious polymorphisms, which may be helpful for vaccine design.

KEYWORDS broadly neutralizing monoclonal antibodies (bN-mAbs), V3-glycan bNAb, envelope pseudoviruses, neutralization resistance, slow progressor

Introduction

Inducing antibodies with cross-neutralizing activity is an important indicator for the effectiveness of HIV-1 vaccine and it remains an unsolved challenge, although broadly neutralizing antibodies (bNAbs) developed in 10–30% of HIV-1 infected individuals after several years' infection, indicating there are no insurmountable barriers for introducing bNAbs in humans by Envelope (Env) (1-5). So far, there is still no immunogen capable of inducing neutralizing antibodies (NAbs) with broad width to tier-2 viruses (6, 7). In 2019, Bricault CA *et al* (8) modified antigens targeting V2-glycan based on the neutralizing signatures of V2-glycan bNAbs, and induced greater breadth of tier 2 NAb responses, indicating the potential usage of researching the resistant mechanisms of HIV-1 to bNAbs in vaccine design.

The glycan supersites of the V3 region on HIV-1 Env form vulnerable targets and are exploited by

broadly neutralizing monoclonal antibodies such as PGT121, PGT128, and PGT135(9). The N332 glycan residue at the base of the V3 loop has been demonstrated to provide an important supersite of vulnerability for extensive antibody-mediated virus neutralization, and is used to aid the design and development of effective vaccines. In the case of these monoclonal antibodies that target the V3-glycan supersite, the loss of glycan at position 332 is often associated with resistance(10). However, there are still quite a lot of circulating strains that harboring this supersite but still resistant to these antibodies(10, 11). Previous studies have speculated that in the presence of N332 glycosylation sites, the longer length of V1/V2 region was associated with V3-glycan bNAbs resistance (8, 11-14), and van den Kerkhof *et al* (11) observed a statistically significant positive correlation between V1 length and neutralization resistance to PGT135. However, these speculations still need to be verified. At the same time, because functionally defined epitopes were distinct from structurally defined epitopes(15), so far, little was known about the determinants conferring neutralization resistance to these viruses. Researching for the mechanisms behind this phenomenon may provide insights for modification of vaccine immunogens and contribute to the design of HIV-1 Env immunogens.

Furthermore, the HIV-1 gp120 protein organization alternates between five constant regions and five variable regions (16) through structural independence, so that the goals of continuous variation and maintenance of function can be ensured. On the one hand, the more accessible variable regions of the immune system can freely undergo extensive sequence diversification to counteract the immune response(17-19); On the other hand, the constant regions are entirely located inside(17, 18), and the more conserved core regions inside provide a scaffold to stabilize the protein structure(20, 21). In the

presence of a wide range of co-evolutionary networks, it is especially a challenge to retain functionality. Understanding the coevolution networks is also an important issue for vaccine design(22, 23), which provide insight for the design of antigenic modifications while retaining its functionality.

In our study, pseudoviruses expressing the CBJC515 autologous Env were constructed, and the neutralizing sensitivity of these pseudoviruses to PGT121, VRC01, 12A21, 10E8, 2G12, and PGT135 were tested. Surprisingly we found all of them were resistant to PGT135. Such patient provided us with a unique opportunity to study this phenomenon. Through site-directed mutation and chimeric experiment, we found multiple mechanisms of escape from PGT135, including through long V1 region, changes in V4/C2 region, or through creating 398/611 glycan site, which explored our knowledge especially on how HIV-1 can escape from PGT135 responses through extreme ways without changing the epitope itself. Furthermore, chimeric experiments also allow us to explore the co-evolution and function maintenance among different regions, we verified the V1V2 diversity has broad interference with Env functionality and the role of V3 region in relieving dramatic decrease in functionality induced by V1V2 or C2, which has been rarely studied(24, 25), and these findings will be useful for vaccine design.

Materials and methods

Study subject

The donor CBJC515 and CBJC437 described in this study were selected from a Chinese HIV-1 subtype B' chronically infected cohort, whose plasma exhibit broad cross-neutralizing activity against a panel of 25 viruses since the first sampling year (26). These patients were infected during commercial

plasma donation between 1992 and 1995 and were antiretroviral treatment (ART)-naive. The major characteristics of CBJC515 were shown in Table 1, and those of CBJC437 were as previously reported(27). The study was reviewed and approved by the Institutional Review Board of the National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention. The subject provided written informed consent before blood and data collection.

Single-genome amplification and envelope clones

Viral RNA was extracted from plasma using QIAamp Viral RNA Mini Kit (Qiagen) and cDNA was immediately synthesized using SuperScript III First-Strand Synthesis System (Invitrogen). Single-genome amplification (SGA) of the full-length gp160 gene was performed as previously described (28). Briefly, the synthesized cDNA was continuously diluted and distributed in replicates of 12 to 16 PCRs in the Thermo Grid 96-well plates to identify a dilution where positive wells accounting for 30% of total PCR reactions. When the SGA criteria of fewer than 30% positive results were met, most of the wells contain amplicons derived from a single cDNA molecule in the appropriate dilution.

The PCR products obtained by SGA were cloned into the commercial directional vector pcDNA3.1D/V5-His-TOPO according to the manufacturer's instructions (Invitrogen). The correct pcDNA3.1-Env plasmid used to produce wild type pdsudoviruses were selected by sequencing. First, transforming the constructed plasmids into E.coli JM109 competent cells (TaKaRa), and then selecting monoclonal E.coli colonies on ampicillin-resistant LB medium for sequencing. The verified correct E.coli clones were cultivated and then the plasmids were extracted using E.Z.N.A.® Plasmid Mini Kit

(Omega) for pseudovirus production. The mutagenesis and chimeric plasmid described below used to produce pseudoviruses were selected as the same way.

Sequence alignment and analysis

SGA were sequenced on an ABI 3770 Sequencer (Applied Biosciences). The full-length gp160 gene fragments for each product were assembled and edited using Sequencher 4.1 (Gene Codes, Ann Arbor, MI). All chromatograms were inspected for sites of mixed bases (double peaks), and any sequence with evidence of double peaks was excluded from further analysis.

The Env nucleotide sequences were aligned by Gene Cutter (https://www.hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html) using HIV-1 HXB2 as reference sequence and the amino acid sequences were deduced by Env nucleotide sequences. Potential N-linked glycosylation sites (PNGS) were identified using N-Glycosite (<http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html>) at the Los Alamos HIV database website; The consensus sequence of CBJC515 and CBJC437 were analyzed by online analysis tool “Consensus Maker” (<https://www.hiv.lanl.gov/content/sequence/CONSENSUS/consensus.html>); LALIGN tool (http://www.ch.embnet.org/software/LALIGN_form.html) was used to calculate sequence identity and similarity between the 2005 Env consensus sequence and each 2005 functional clones; Chinese subtype B database set (named “B-Database”) containing a total of 168 sequences were selected from Los Alamos HIV database (<https://www.hiv.lanl.gov/components/sequence/HIV/search/search.html>) according to the keywords “china”, “subtype B”, “intact gp120 sequences” and “one sequence/patient”.

135 **Generation of site-directed mutagenesis and chimeric clones**

136 Site-directed mutagenesis was performed by standard PCR procedure. Approximately 50 ng plasmid
137 DNA template, 1 μ L of 1 μ M primer F (forward), R (reverse), were added into the PCR mixture
138 containing 4 μ L dNTP mixture (2.5 mM), 25 μ L 2 $\times$ PrimeSTAR GC buffer (TaKaRa), 0.5 μ L
139 PrimeSTARWHS DNA polymerase (2.5 U/ μ L) (TaKaRa) and ddH₂O, with a total volume of 50 μ L.
140 The primer F was designed according to the nucleic acid sequence of 5 amino acid positions before and
141 after the mutation site, and the primer R was reverse and complement to the primer F. Cycling
142 conditions for this PCR are 98°C for 1 min, followed by 30 cycles of 98°C for 10 s, 56°C for 20 s (the
143 annealing temperature can be adjusted according to different primers), and 72°C for 6 min, with a final
144 extension at 72°C for 10 min. The entire Env gene of each mutant was sequenced to confirm mutation.

145 Chimeric clones were conducted by GeneArt® Seamless Cloning and Assembly Kit (Invitrogen),
146 which can assemble several linearized DNA fragments into one DNA sequence. The inserted nucleotide
147 fragments were synthesized (Sangon Biotech). The backbone of Env plasmid to be replaced were
148 linearly amplified by PCR, and the PCR products were verified on a 0.8% agarose gel and then
149 subjected to gel extraction using QIAquick Gel Extraction Kit (Qiagen). The two ends of the linear
150 amplification primers were designed to overlap with synthesized insertion protein sequence with 15bp
151 bases respectively, so the two parts were able to be seamlessly linked through the assembly kit
152 (Invitrogen). The integrity of the chimeric plasmids was confirmed by sequencing and restriction
153 analysis as described above. Finally, the boundaries of regions changed after chimeric were as follows:

131-135 for V1 region, 158-196 for V2 region, 131-196 for V1V2 region, 197-295 for C2 region, 296-331 for V3 region, 385-418 for V4 region, and 131-331 for V1-V3 region. The numbers refer to the amino acids position of HXB2 gp120 protein.

Pseudovirus preparation, and titration for neutralization assays

Pseudoviruses were prepared, titrated as previously described(27). Briefly, 293T cells were cotransfected with pcDNA3.1-Env clone and Env-deficient HIV-1 backbone vector (pSG3 Δ Env) using PEI transfection reagent (PolyScience). Pseudovirus-containing supernatant was harvested 48h post-transfection, and then filtered (0.45 μ m pore size) and stored at -80°C. The 50% tissue culture infectious dose (TCID₅₀) of a single-thawed aliquot of each pseudovirus batch was determined in TZM-bl cells.

Neutralization assay

Neutralization was measured as a reduction in Luc reporter gene expression after a single round of virus infection in TZM-bl cells as described previously (26). Briefly, 50 μ L of pseudotyped viruses normalized to 4000 TCID₅₀/mL was incubated with 100 μ L serial threefold dilutions of broadly neutralizing monoclonal antibodies (bN-mAbs) in duplicate for 1 h at 37°C in 96-well flat-bottom culture plates. The virus-antibody mixture was then used to infect 10,000 TZM-bl cells in the presence of 30 μ g/mL DEAE-dextran. One set of the control wells received cells only, while the other set received pseudovirus plus cells. Infection levels were determined after 48h by measuring the luciferase activities of cell lysates. After 48 hours of incubation, 150 μ L of the culture was removed, and 100 μ L of

Ultra-High Sensitivity Luminescence Reporter Gene Assay System (PerkinElmer) was added and incubated for 2 minutes. luciferase activities of 150 µl lysate transferred from each well to a 96-well black solid plate were measured by a luminometer (PerkinElmer). The 50% inhibitory dose (ID50) was defined as either the plasma dilution or sample concentration at which relative luminescence units (RLU) were reduced 50% compared to virus control wells.

Neutralizing antibodies used in the study

bN-mAbs PGT135, PGT121, 2G12, 12A21, 10E8, and VRC01 were kindly received from NIH AIDS Research and Reference Reagent Program.

Data availability

Env sequences from CBJC515 and CBJC437 donors have been deposited into GenBank and the accession numbers were shown in Table 2 and Supplementary Table 1.

Results

Sensitivity to neutralization by broadly neutralizing monoclonal antibodies (bN-mAbs)

6, 3, 11 pseudoviruses were successfully constructed from CBJC515 plasma samples at 20050816, 20060418, and 20081118 time points, named 05/06/08 isolates respectively, and we examined the sensitivity of these isolates to prototypic bNAbs PGT121, VRC01, 12A21, 10E8, 2G12 and PGT135 (Table 2). Almost all 20 clones were sensitive to the CD4 binding site (CD4bs) specific bN-mAb VRC01, 12A21, and membrane proximal external domain (MPER) specific bN-mAb 10E8. As to the bN-mAbs

recognizing N332-supersite (9, 29), all clones were resistant to PGT135 but sensitive to PGT121, while all 05 strains were resistant to 2G12.

Lack of 332 glycosylation site leads to resistance to PGT135 in 05 isolates

Since all clones from CBJC515 were resistant to the V3-glycan bNAb PGT135, this aroused our great interest. PGT135 interacts with glycans at Asn332, Asn386 and Asn392, using long CDR loops H1 and H3 to penetrate the glycan shield to access the gp120 protein surface(9). We first analyzed the 332 position of these strains. As shown in Table 3, the N332 glycan site was generally missing in 05 Env clones, but all 06/08 clones contained this supersite. In 05 isolates, strain 05-8 lacks 332 N-glycan site due to the presence of aspartic acid at this position (referring to the relative position on the HXB2 strain, the same below), while others possess N334 glycan site, which also leads to lack of 332 N-glycan site. We performed D332N or N334S mutations on 05 isolates, and all of them became sensitive to PGT135 and 2G12 (Table 4). In addition, we checked other epitopes reported in literatures (8, 9, 30) that associated with PGT135 neutralizing sensitivity(Table 3), and performed R/K389Q, T409E or Y330H mutation to the corresponding strains, but no changes were found.

In our study, PGT135 and 2G12 were completely unable to neutralize the 05 pseudoviruses containing N334 glycan site, while PGT121 was able to neutralize all of them. Previous studies have shown that some N332-dependent bNAbs can recognize promiscuous glycans with different ability, and some can neutralize strains transferred glycosylation site to N334(9, 10). Our observations were consistent with it.

210 **Chimeric experiment examines effect of different regions on neutralizing sensitivity of 06/08** 211 **isolates**

212 We further explored the determinants conferring neutralization resistance to 06/08 strains with key
213 epitopes (Table 3). Sequence analysis showed that 05 isolates had shorter V1 region of 22 amino acids
214 (aa) with higher similarity, while the 06/08 strains expanded V1 region pronouncedly (22-42 aa long)
215 and was much longer than HIV-1 subtype B consensus sequence (25 aa) (13) (Fig. 2). By replacing the
216 V1 region (position 131-157) of 06/08 Env clones to 05-8 (D332N), which was selected as the most
217 representative strains of 05 clones through sequence harmony (SH) method compared with 05 Env
218 consensus sequence (Table 5), we assessed whether longer V1 loop was associated with neutralizing
219 resistance to PGT135 (11, 13).

220 11 V1 chimeras were successfully constructed (Fig. 2 and Table 6). Among them, 6 chimeras were
221 not able to produce infectious clones (the wild type V1 length varied from 22 to 42 amino acids), 2
222 chimeric strains 08-2 (05-8 V1), 08-12 (05-8 V1) were still resistant to PGT135 (the original V1 length
223 was 33, 37 amino acids respectively), and 3 chimeric strains, 08-8 (05-8 V1), 08-11 (05-8 V1) and 08-13
224 (05-8 V1), became sensitive to PGT135 with the IC₅₀ of 1.19 ug/ml, 5.8 ug/ml, and 8.3 ug/ml.

225 Since the V1V2 region is a global regulator of neutralizing sensitivity(31-34), previous studies also
226 shown that the neutralizing ability of some V3-glycan bNAbs were associated with the length of V1V2
227 region in the presence of N332 glycan site, and the longer the virus in the V1+V2 region, the more
228 difficult it was to be neutralized (8). Therefore, we also construct 7 V1V2 chimeras by replacing the
229 V1V2 region of 06/08 strains with that of 05-8 (Table 6). Our neutralizing experiment showed 5 of them

lose functionality, and only two chimeras 08-2 (05-8 V1V2) and 08-12 (05-8 V1V2) were functional but still resistant. Furthermore, we constructed 3 V2 chimeric clones (Table 6), and there was only 1 chimera was functional and remaining resistant. So, it seems like, among the V1V2 region, V1 loop was the most important part to confer resistance to these strains.

Based on the above results, we further examined whether changes in other regions except for V1 would affect its sensitivity to PGT135 as the virus evolving at subsequent 06/08 time points. Chimeric envelopes were generated by replacing the C2, V3, V1-V3 or V4 region of 06/08 isolates with the corresponding region of 05-8 (D332N) (Table 7 and Fig. 1). Neutralization experiment showed all the 6 V3 chimeras did not change sensitivity to PGT135 (Fig. 3). In the 4 C2 chimeras, 3 were functional and 1 was sensitive. 10/12 V1-V3 chimeras were functional with 3 of them became sensitive, while 2/3 V4 chimeras were functional and all the 2 chimeras were sensitive.

N611A and N398A mutation may have Impact on Neutralizing sensitivity to PGT135

To further explore the resistant mechanisms in 06/08 isolates, we selected another Chinese subtype B' slow progressor CBJC437, whose isolates were also containing key epitopes such as N332/N386/N392/N295/H330 and were sensitive to PGT135 (Table S1). According to the consensus sequence alignment, we selected the different sites of the two samples in V3/V4 region (Fig. 4), which was most likely to influence the neutralizing sensitivity(9), to perform mutations on 3-4 strains of CBJC515 changing the amino acids to the corresponding signature of CBJC437 isolates. However, no mutations were found to have effect on the neutralization. Furthermore, we also compared all the N-glycosylation sites among the two samples, and selected the unique N-glycan site of each sample

(since the V1 region has changed a lot, we didn't consider the unique glycosylation sites in the V1 region) (Fig. 4). We only found the N398A mutation in 06-4/08-13 and N611A mutation in 08-9 restored sensitivity to PGT135 with the IC₅₀ of 7.23 ug/ml, 6.91 ug/ml and 2.64 ug/ml respectively, in a strain-specific way (Table S2-S3).

Statistical analysis of key glycosylation sites of PGT135 in Chinese HIV-1 subtype B strains

According to previous reports, the neutralization breadth of PGT135 was about 33%, which was comparable to the CD4bs-class antibody b12, but lower than other N332-dependent antibodies such as PGT121 and PGT128 (29). This lower neutralization width was reported mainly due to the limited prevalence of key contact residues, such as Asn332, Asn392 and His330, in circulating strains(9).

We downloaded 168 sequences of Chinese subtype B strains from Los Alamos HIV database (named B-Database), and made statistics on the key neutralizing epitopes of PGT135. H330, N332 and N392, which are necessary for PGT135 neutralization, were present in 76% (127/168) sequences of B-Database. As PGT135 can recognize N295 and N386 glycans in a strain-dependent manner(9), we also calculate the prevalence of H330, N332, N392 and N295 or N386, and the ratio was 66% (111/168) and 67% (112/168) respectively. At the same time, all the four N-glycan site, N332 N392 N295 and N386, appeared in 60% (100/168) of the sequences, and the ratio of single glycosylation site at position 332 accounted for 93.5% (157/168). The prevalence of these key sites was significantly higher than the 33% neutralization width of PGT135. It can be speculated that a large part of the Chinese HIV-1 subtype B strains containing key epitopes of PGT135 may able to escape from it. Therefore, it will be very meaningful to explore the resistant mechanisms of these strains.

270 Discussion

271 The generation of bNAbs responses through vaccination is still an essential question in HIV research.
 272 Knowing the escaping mechanisms in broad cross-neutralizing samples may yield useful information for
 273 vaccine design (14, 35-37). In our research, escape from PGT135 was mediated via multiple pathways.
 274 Except for the absence of N332-supersite, the resistant strains harboring all key epitopes may escape
 275 through changing V1/V4/C2 region, or through N398/N611glycan. Previous study speculated strains
 276 may escape from PGT135 through longer V1 region(11), and in our research, we verified it can indeed
 277 restore the sensitivity in some strains, while the V1V2 or single V2 replacement cannot. Together with
 278 previous study about PGT121 and PGT128(10, 12, 38), our finding highlighted the broad effect of long
 279 V1 region on neutralizing activity to V3-glycan bNAbs which may through blocking access to the
 280 V3-glycan supersite(14). We also found V4 and C2 region may affect its neutralization. Through our
 281 large amount of site-directed mutations, we found it very difficult to restore neutralizing sensitivity by
 282 changing single amino acid. Our observations thus suggested that extreme variations may be needed to
 283 escape from PGT135 in strains with N332-supersite(13).

284 In the CBJC515 donor, over the course of infection, the locations of PNGS were altered. Strains
 285 evolved from 2005 strains without N332 glycosylation site to the isolates with 332 N-glycan gradually
 286 fixing in 2006/2008 timepoint. The usual mode of escape from the V3-carbohydrate class of potent
 287 broadly neutralizing antibodies is via mutation of the N332 glycan(10), so it can be speculated that
 288 samples from time points prior to 2005 may contain V3-glycan bNAbs such as PGT135-like. After the
 289 year 2005, We speculated that the retention of the N332 epitope may be due to selection pressure from

strain specific NAb or other antibody lineages (14, 35) as time went on. In order to escaping from them, strains produced N332-glycosylation site and adopted these unusual escaping routes. The neutralization width of CBJC515 fluctuated continuously from 2005 to 2009 timepoint (Table 1) and previously study which suggesting different lineages of antibody co-exist in this sample(39) supporting our prediction. In natural infection, bNAbs usually take several years to evolve, suggesting a requirement for prolonged antigen exposure (36, 40, 41). In CBJC515, the retention of N332 site through extreme escape routes may help to prolong the exposure of bNAb epitopes, which may assist its maturation as mentioned in previous reports (14, 35-37), and it was supported by our results of incomplete viral escape in contemporaneous neutralization (data not shown). The explanation and speculation of the unusual escaping mode in CBJC515 donor may need to be further explored, such as by plasma epitope mapping and B-cell sequencing.

Genetic diversity and coevolution are essential for HIV-1 to get rid of the host immune response. Extensive coevolution of structurally and functionally related parts of the protein is the solution for the virus to conciliate genetic diversity and maintain functionality. For these aspects, there have been few reports in the past(24, 25), and our chimeric experiment provided materials for the investigation.

As the outermost part of the viral particle, gp120 is the virus component most vulnerable to immune stress, and therefore, may be the most important protein for genetic diversity. Although V1V2 region might preserve the functionality of the protein with only minor structural constraints while they have evolved to maximize their possibility of sequence diversification, the replacement of variable region abolishes Env functionality in 5/7 V1V2 chimeras, 6/11 V1 chimeras and 2/3 V2 chimeras (Table

6 and Fig. 3b), which indicated the broader validity of V1V2 region in interference with the functionality of envelope protein (25). In addition, there were 1/3, 1/4 non-functional clones in V4, C2 chimeras, respectively (Table 7 and Fig. 3b). The non-functional clones after the replacement of these regions reflect the important significance of co-evolution among each region of the strain for function maintenance.

As it has been reported that the replacement of V3 usually has less impact on Env function(25), we did not find any non-functional clones through chimeric V3 region (Fig. 3a). The higher conservation level of V3 region may reflect the requirement to maintain the optimal conformation required for the co-receptor binding site and explain why the replacement of this domain is more tolerant than other regions(42). When we replace the V1-V3 region (including V1, V2, C2, V3), there were only 2/12 chimeras showed non- functionality (Fig. 3b). This extremely low probability of non-functionality compared with the single exchange of V1/V2/C2 region, in addition to reflecting the coevolution of V1-V3 region, it also reflects the role of V3 in promoting function recovery. Taking the 06-4 strain as an example, chimeric with V1V2 and C2 region all abolished its functionality, while V1-V3 chimeras restored. A recent study support our finding of the role of V3 region in buffering deleterious effect of polymorphisms and increasing genetic robustness (24), and this study also pointed out that the defect of C2 chimera may be blocked after recognizing the co-receptor CCR5 due to interference with the subsequent conformation of membrane fusion changes.

Finally, we deepened the understanding of the pathways that may affect the accessibility of PGT135 to its epitopes and highlighted the complexity and extremely ways of resistant mechanisms to

PGT135 under the condition of harboring key epitopes which verified and supplemented the previous results. We speculated that these unusual ways may play an auxiliary role in the development of bNAb and may be related to the maintenance of long-term highly broad cross-neutralizing activity, although it needs further exploration. The chimeric experiment also verified the importance of coevolution of structurally and functionally related parts of Env for the virus to conciliate genetic diversity and maintain functionality, especially the role of V3 region in the retention of functionality. Altogether, our findings may be helpful for the design of antigenic modifications while retaining its functionality.

ACKNOWLEDGMENTS

This work was supported by the grant from the National Natural Science Foundation of China (81172809, 31411130194), the National Major Project for Infectious Disease Control and Prevention (2016ZX10001-008, 2018ZX10731-101), the SKLID key project (2019SKLID602) and International Cooperation Grant from the Ministry of Science and Technology of China (2016YFE0107600). We are grateful to the CAVD HIV Specimen Cryorepository (HSC) for their contribution of HIV-1 Env-pseudotyped viruses for this study.

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTION STATEMENT

348 SS, LM, YS and KH conceived and designed the study. SS, SZ, YH, YL, LR and YLH performed
349 the experiment. SS, YL, XH, YR and KH analyzed the data and edited the manuscript. All authors have
350 read and approved the final manuscript.

351

352 References

- 353 1. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW,
354 Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, Mascola JR, Connors M. 2009.
355 Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from
356 patients with broadly cross-neutralizing antibodies. *J Virol* 83:188-99.
357 <https://doi.org/10.1128/JVI.01583-08>
- 358 2. Euler Z, van den Kerkhof TL, van Gils MJ, Burger JA, Edo-Matas D, Phung P, Wrin T,
359 Schuitemaker H. 2012. Longitudinal analysis of early HIV-1-specific neutralizing activity in
360 an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. *J*
361 *Virol* 86:2045-55. <https://doi.org/10.1128/JVI.06091-11>
- 362 3. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K,
363 Sibeko S, Williamson C, Abdool Karim SS, Morris L, Team CS. 2011. The neutralization
364 breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell
365 decline and high viral load during acute infection. *J Virol* 85:4828-40.
366 <https://doi.org/10.1128/JVI.00198-11>
- 367 4. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. 2011. Characteristics of the
368 earliest cross-neutralizing antibody response to HIV-1. *PLoS Pathog* 7:e1001251.
369 <https://doi.org/10.1371/journal.ppat.1001251>
- 370 5. van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H. 2009. Prevalence of
371 cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow
372 disease progression. *AIDS* 23:2405-14. <https://doi.org/10.1097/QAD.0b013e32833243e7>
- 373 6. Sanders RW, Moore JP. 2017. Native-like Env trimers as a platform for HIV-1 vaccine design.
374 *Immunol Rev* 275:161-182. <https://doi.org/10.1111/imr.12481>
- 375 7. Pancera M, Changela A, Kwong PD. 2017. How HIV-1 entry mechanism and broadly
376 neutralizing antibodies guide structure-based vaccine design. *Curr Opin HIV AIDS*
377 12:229-240. <https://doi.org/10.1097/COH.0000000000000360>
- 378 8. Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P,
379 Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL,
380 Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Cheneau C, Jones JJ, Zeng
381 J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams
382 LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B. 2019. HIV-1
383 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. *Cell*
384 *Host Microbe* 25:59-72.e8. <https://doi.org/10.1016/j.chom.2019.07.016>
- 385 9. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse
386 PJ. 2013. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope
387 glycoprotein gp120. *Nature Structural & Molecular Biology* 20:796-803.
- 388 10. Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, Kulp DW, Julien JP, Menis S,
389 Wickramasinghe L, Seaman MS, Schief WR, Wilson IA, Poignard P, Burton DR. 2014.

- Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. *Sci Transl Med* 6:236ra63. <https://doi.org/10.1126/scitranslmed.3008104>
11. van den Kerkhof TL, de Taeye SW, Boeser-Nunnink BD, Burton DR, Kootstra NA, Schuitemaker H, Sanders RW, van Gils MJ. 2016. HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. *Retrovirology* 13:48. <https://doi.org/10.1186/s12977-016-0279-4>
 12. Deshpande S, Patil S, Kumar R, Hermanus T, Murugavel KG, Srikrishnan AK, Solomon S, Morris L, Bhattacharya J. 2016. HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms. *Retrovirology* 13:60. <https://doi.org/10.1186/s12977-016-0297-2>
 13. Silver ZA, Dickinson GM, Seaman MS, Desrosiers RC. 2019. A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection. *J Virol* 93:e00094-19. <https://doi.org/10.1128/JVI.00094-19>
 14. Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, Karim SSA, Morris L, Wood NT, Moore PL, Williamson C. 2017. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope. *J Virol* 91:e00828-17. <https://doi.org/10.1128/JVI.00828-17>
 15. Dingens AS, Arenz D, Weight H, Overbaugh J, Bloom JD. 2019. An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes. *Immunity* 50:520-532 e3. <https://doi.org/10.1016/j.immuni.2018.12.017>
 16. Starcich BR, Hahn BH, Shaw GM, McNeely PD, Modrow S, Wolf H, Parks ES, Parks WP, Josephs SF, Gallo RC, et al. 1986. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. *Cell* 45:637-48. [https://doi.org/10.1016/0092-8674\(86\)90778-6](https://doi.org/10.1016/0092-8674(86)90778-6)
 17. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. *Nature* 422:307-12. <https://doi.org/10.1038/nature01470>
 18. Mascola JR, Montefiori DC. 2010. The role of antibodies in HIV vaccines. *Annu Rev Immunol* 28:413-44. <https://doi.org/10.1146/annurev-immunol-030409-101256>
 19. Reitter JN, Means RE, Desrosiers RC. 1998. A role for carbohydrates in immune evasion in AIDS. *Nat Med* 4:679-84. <https://doi.org/10.1038/nm0698-679>
 20. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC. 2005. Structure of an unliganded simian immunodeficiency virus gp120 core. *Nature* 433:834-41. <https://doi.org/10.1038/nature03327>
 21. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC,

- Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. *Nature* 480:336-43. <https://doi.org/10.1038/nature10696>
22. Kwon YD, Pancera M, Acharya P, Georgiev IS, Crooks ET, Gorman J, Joyce MG, Guttman M, Ma X, Narpala S, Soto C, Terry DS, Yang Y, Zhou T, Ahlsen G, Bailer RT, Chambers M, Chuang GY, Doria-Rose NA, Druz A, Hallen MA, Harned A, Kirys T, Louder MK, O'Dell S, Ofek G, Osawa K, Prabhakaran M, Sastry M, Stewart-Jones GB, Stuckey J, Thomas PV, Tittley T, Williams C, Zhang B, Zhao H, Zhou Z, Donald BR, Lee LK, Zolla-Pazner S, Baxa U, Schon A, Freire E, Shapiro L, Lee KK, Arthos J, Munro JB, Blanchard SC, Mothes W, Binley JM, et al. 2015. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. *Nat Struct Mol Biol* 22:522-31. <https://doi.org/10.1038/nsmb.3051>
23. Mann JK, Ndung'u T. 2015. HIV-1 vaccine immunogen design strategies. *Virol J* 12:3. <https://doi.org/10.1186/s12985-014-0221-0>
24. Gasser R, Hamoudi M, Pellicciotta M, Zhou Z, Visdeloup C, Colin P, Braibant M, Lagane B, Negroni M. 2016. Buffering deleterious polymorphisms in highly constrained parts of HIV-1 envelope by flexible regions. *Retrovirology* 13:50. <https://doi.org/10.1186/s12977-016-0285-6>
25. Hamoudi M, Simon-Lorieri E, Gasser R, Negroni M. 2013. Genetic diversity of the highly variable V1 region interferes with Human Immunodeficiency Virus type 1 envelope functionality. *Retrovirology* 10:114. <https://doi.org/10.1186/1742-4690-10-114>
26. Hu X, Hong K, Zhao C, Zheng Y, Ma L, Ruan Y, Gao H, Greene K, Sarzotti-Kelsoe M, Montefiori DC, Shao Y. 2012. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy. *J Gen Virol* 93:2267-78. <https://doi.org/10.1099/vir.0.043802-0>
27. Zhang D, Zou S, Hu Y, Hou J, Hu X, Ren L, Ma L, He X, Shao Y, Hong K. 2019. Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity. *Front Microbiol* 10:1096. <https://doi.org/10.3389/fmicb.2019.01096>
28. Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose N, Hoxie JA, Connors M, Shaw GM, Wyatt RT, Mascola JR. 2012. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. *J Virol* 86:5844-56. <https://doi.org/10.1128/JVI.07139-11>
29. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Protocol GPI, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. *Nature* 477:466-70. <https://doi.org/10.1038/nature10373>

30. Ferguson AL, Falkowska E, Walker LM, Seaman MS, Burton DR, Chakraborty AK. 2013. Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data. PLoS One 8:e80562. <https://doi.org/10.1371/journal.pone.0080562>
31. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. 2004. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 78:5205-15. <https://doi.org/10.1128/jvi.78.10.5205-5215.2004>
32. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, Pollara J, Rao M, Peachman KK, Santra S, Letvin NL, Karasavvas N, Yang ZY, Dai K, Pancera M, Gorman J, Wiehe K, Nicely NI, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Sinangil F, Kim JH, Michael NL, Kepler TB, Kwong PD, Mascola JR, Nabel GJ, Pinter A, Zolla-Pazner S, Haynes BF. 2013. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38:176-86. <https://doi.org/10.1016/j.immuni.2012.11.011>
33. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Prem Sri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, Investigators M-T. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209-20. <https://doi.org/10.1056/NEJMoa0908492>
34. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Margaret CA, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, McLellan JS, Georgiev I, Kwong PD, Carlson JM, Michael NL, Schief WR, Gilbert PB, Mullins JI, Kim JH. 2012. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490:417-20. <https://doi.org/10.1038/nature11519>
35. Gao F, Bonsignori M, Liao HX, Kumar A, Xia SM, Lu X, Cai F, Hwang KK, Song H, Zhou T, Lynch RM, Alam SM, Moody MA, Ferrari G, Berrong M, Kelsoe G, Shaw GM, Hahn BH, Montefiori DC, Kamanga G, Cohen MS, Hraber P, Kwong PD, Korber BT, Mascola JR, Kepler TB, Haynes BF. 2014. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 158:481-91. <https://doi.org/10.1016/j.cell.2014.06.022>
36. Bonsignori M, Zhou T, Sheng Z, Chen L, Gao F, Joyce MG, Ozorowski G, Chuang GY, Schramm CA, Wiehe K, Alam SM, Bradley T, Gladden MA, Hwang KK, Iyengar S, Kumar A, Lu X, Luo K, Mangiapani MC, Parks RJ, Song H, Acharya P, Bailer RT, Cao A, Druz A, Georgiev IS, Kwon YD, Louder MK, Zhang B, Zheng A, Hill BJ, Kong R, Soto C, Program NCS, Mullikin JC, Douek DC,

- Montefiori DC, Moody MA, Shaw GM, Hahn BH, Kelsoe G, Hraber PT, Korber BT, Boyd SD, Fire AZ, Kepler TB, Shapiro L, Ward AB, Mascola JR, Liao HX, et al. 2016. Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. *Cell* 165:449-63. <https://doi.org/10.1016/j.cell.2016.02.022>
37. Moore PL, Sheward D, Nonyane M, Ranchobe N, Hermanus T, Gray ES, Abdool Karim SS, Williamson C, Morris L. 2013. Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. *J Virol* 87:4882-94. <https://doi.org/10.1128/JVI.03424-12>
38. Goo L, Jalalian-Lechak Z, Richardson BA, Overbaugh J. 2012. A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection. *J Virol* 86:10857-61. <https://doi.org/10.1128/JVI.01414-12>
39. Li D, Wang Z, Ren L, Zhang J, Feng G, Hong K, Hao Y, Qi Z, Liang H, Shao Y. 2016. Study of antibody repertoires to the CD4 binding site of gp120 of a Chinese HIV-1-infected elite neutralizer, using 454 sequencing and single-cell sorting. *Arch Virol* 161:789-99. <https://doi.org/10.1007/s00705-015-2710-x>
40. Xiao X, Chen W, Feng Y, Dimitrov DS. 2009. Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies. *Viruses* 1:802-17. <https://doi.org/10.3390/v1030802>
41. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu RB, Fu BZ, Gnanapragasam PN, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ, Nussenzweig MC. 2013. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. *Cell* 153:126-38. <https://doi.org/10.1016/j.cell.2013.03.018>
42. Zolla-Pazner S, Cardozo T. 2010. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. *Nat Rev Immunol* 10:527-35. <https://doi.org/10.1038/nri2801>

534 Legends

535 **FIG 1** Schematic representation of the chimeric HIV-1 envelopes used in this study. The C1-C5
536 structure of the 05-8 envelope gene is given at the top, with the constant and variable regions of the
537 gp120 region in green and yellow, respectively. In the 06/08 wildtype receiver protein, the backbone of
538 constant and variable region is shown in dark blue and light blue, respectively.

539 **FIG 2** The alignment of V1 region. CON B representing the HIV-1 subtype B consensus sequence was
540 from reference(13). Sequence position corresponding to reference strain HXB2 is 131-157. The nucleic
541 acid with gray, dark gray, and black background represents common amino acid sequences. Gaps in the
542 amino acid sequence are shown with a dash (-). The rightmost number shows the length of V1 region.
543 The names of sensitive chimeras are in red background, resistant chimeras are in yellow background,
544 and non-functional chimeras are in gray background.

545 **FIG 3** V3 alignment (a) and ratio of non-functional chimeras when chimeric with V1, V2, V1V2, C2,
546 V3, V1-V3, and V4 region (b). The nucleic acid with Gray, dark gray, and black background represent
547 common amino acid sequences. Resistant chimeras are in yellow background.

548 **FIG 4** Alignment of the consensus sequence between CBJC515 and CBJC437. Numbers with Asterisks
549 represent potential glycosylation sites; Blue fonts and red fonts represent CBJC515-specific and
550 CBJC437-specific glycosylation sites (excluding V1 region) respectively by N-Glycosite analysis;
551 Yellow fonts represent different non-glycosylation sites among V3/V4 regions between CBJC515 and
552 CBJC437 consensus sequence. The arrows and the above numbers represent the boundaries of each
553 variable and constant region.

554

TABLE 1 Major characteristics of CBJC515 donor

Sample date	No.of CD4+ T cells/ μ L	No.of viral RNA copies/mL	Geometric mean ID50 titres	No.of functional clones	Breath
20050816	528	1.97E+04	-	6	-
20051101	530	6.94E+03	61.7	-	77.3%
20060418	536	1.55E+04	161.6	3	90.9%
20061123	476	2.90E+04	203.0	-	95.5%
20070424	543	6.69E+03	106.0	-	81.8%
20080415	459	2.22E+04	-	-	-
20081118	321	1.25E+05	94.1	11	86.4%
20090519	268	8.56E+04	164.8	-	95.5%

“-” indicates no data were obtained.

TABLE 2 Neutralization sensitivity of CBJC515 pseudoviruses to representative broadly neutralizing monoclonal antibodies (bN-mAbs)

Functional clones	Accession number	IC50(μ g/mL)					
		PGT121	VRC01	12A21	10E8	2G12	PGT135
05-3	MF591587	0.73	0.06	15.21	0.96	>10	>10
05-4	MF591591	0.79	0.15	12.12	0.22	>10	>10
05-5	MF591593	1.27	0.11	0.07	0.33	>10	>10
05-6	MF591594	1.82	0.09	0.05	0.31	>10	>10
05-8	MF591596	0.75	0.077	>10	0.26	>10	>10
05-9	MF591597	1.77	0.24	17.39	0.42	>10	>10
06-1	MF591619	1.19	4.76	4.09	3.05	0.62	>10
06-2	MF591620	5.79	2.11	1.91	0.68	0.89	>10

06-4	MF591622	0.45	1.88	1.12	1.24	0.47	>10
08-1	MF591660	0.2	3.54	2.63	0.86	0.67	>10
08-2	MF591661	0.8	4.18	3.11	2.17	0.77	>10
08-4	MF591663	6.67	6.24	0.36	0.92	3.37	>10
08-6	MF591665	0.7	3.5	3.12	0.14	0.71	>10
08-7	MF591666	2.1	0.08	5.29	0.31	>10	>10
08-8	MF591667	0.31	4.76	0.44	0.43	5.42	>10
08-9	MF591669	0.47	3.09	1.99	0.88	0.58	>10
08-10	MF591670	1.11	3.81	0.1	0.28	0.91	>10
08-11	MF591671	0.48	4.25	2.32	0.5	0.46	>10
08-12	MF591672	2.97	2.31	1.27	0.73	2.37	>10
08-13	MF591673	0.19	2.84	0.68	0.7	0.5	>10

560 “>10” means couldn’t be neutralized by PGT135.

561

562 **TABLE 3** The condition of epitopes for PGT135 in 2005, 2006 and 2008 functional Env clones

Env clones	N-glycan site				Q389	E409	H330
	332	295	386	392			
05-3	-	+	+	+	R	T	.
05-4	-	+	+	+	R	T	.
05-5	-	+	+	+	R	T	.
05-6	-	+	+	+	R	T	.
05-8	-	+	+	+	R	T	.
05-9	-	+	+	+	R	T	.
06-1	+	+	+	+	K	T	.
06-2	+	+	+	+	K	T	.

06-4	+	+	+	+	K	T	.
08-1	+	+	+	+	K	T	.
08-2	+	+	+	+	K	T	.
08-4	+	+	+	+	K	T	Y
08-6	+	+	+	+	K	T	.
08-7	+	+	+	+	R	T	.
08-8	+	+	+	+	K	T	Y
08-9	+	+	+	+	K	T	.
08-10	+	+	+	+	K	T	Y
08-11	+	+	+	+	K	T	.
08-12	+	+	+	+	K	T	Y
08-13	+	+	+	+	K	T	Y

“+” indicates that the sequence has a potential N-glycosylation site on the position shown on the top; “-” indicates no N-glycosylation site on the corresponding site; “.” indicates the amino acid was consistent with epitope on the top.

TABLE 4 The neutralizing sensitivity of mutations to PGT135

Mutant clones	IC50(ug/mL)	
	PGT135	2G12
05-8 (D332N)	0.57	1.76
05-3 (N334S)	6.68	0.82
05-4 (N334S)	1.54	1.89
05-5 (N334S)	0.66	0.97
05-6 (N334S)	5.05	>10

05-9 (N334S)

0.90

1.66

“>10” means couldn’t be neutralized by PGT135.

TABLE 5 Similarity of amino acid sequence of consensus 05 functional Env with other 05 functional Envs

05 Envs	% Identity ^a	% Similarity ^b
Con 05	100.0	100.0
05-3	98.0	99.5
05-8	99.5	99.6
05-4	99.3	99.5
05-5	99.3	99.5
05-6	98.5	99.3
05-9	98.7	99.5

^a% identity’ refers to the degree of correlation between two un-gapped sequences and indicates that the amino acid at the particular position is an exact match. ^b% similarity’ refers to the degree of resemblance between two sequences and indicates that the amino acids at a particular position have some properties in common (e.g., charge or hydrophobicity) but are not identical.

TABLE 6 Neutralizing sensitivity of V1/V1V2/V2 chimeras to PGT135

06、08 Chimeric clones	IC50(ug/ml)
V1 chimera	
06-2(05-8 V1)	-
06-4(05-8 V1)	-
08-1(05-8 V1)	-

08-2(05-8 V1)	>10
08-7(05-8 V1)	-
08-8(05-8 V1)	1.19
08-9(05-8 V1)	-
08-10(05-8 V1)	-
08-11(05-8 V1)	5.8
08-12(05-8 V1)	>10
08-13(05-8 V1)	8.3
V1V2 chimera	
08-1(05-8 V1V2)	-
08-2(05-8 V1V2)	>10
08-8(05-8 V1V2)	-
06-4(05-8 V1V2)	-
08-10(05-8 V1V2)	-
08-11(05-8 V1V2)	-
08-12(05-8 V1V2)	>10
V2 chimera	
08-8(05-8 V2)	-
08-10(05-8 V2)	-
08-12(05-8 V2)	>10

578 “-” indicates non-functional chimera; “>10” means couldn’t be neutralized by PGT135.

579

580 **TABLE 7** Neutralizing sensitivity of C2/V4/V1-V3 chimeras to PGT135

06、08 Chimeric clones	IC50(ug/ml)
C2 Chimera	

06-4(05-8 C2)	-
08-4(05-8 C2)	8.3
08-10(05-8 C2)	>10
08-12(05-8 C2)	>10
V4 Chimera	
06-1(05-8 V4)	2.74
08-2(05-8 V4)	-
08-6(05-8 V4)	0.26
V1-V3 Chimera	
06-1(05-8 V1-V3)	>10
06-4(05-8 V1-V3)	>10
08-1(05-8 V1-V3)	-
08-2(05-8 V1-V3)	>10
08-4(05-8 V1-V3)	>10
08-6(05-8 V1-V3)	>10
08-8(05-8 V1-V3)	4.77
08-9(05-8 V1-V3)	>10
08-10(05-8 V1-V3)	2.6
08-11(05-8 V1-V3)	-
08-12(05-8 V1-V3)	1.18
08-13(05-8 V1-V3)	>10

581 “-” indicates non-functional chimera; “>10” means couldn’t be neutralized by PGT135.

	131		157	
HXB2	CTDLKNDTNTNS-----SSGRMIMEK	GGEIKNC	27	
CON B	CTDLMNATNTNT-----TI--IYRWR	GGEIKNC	25	
05-8	CADLRNTTNN-----SSTTEG	GGEIKNC	22	
05-3	CADLRNTTNT-----SITTEG	GGEIKNC	22	
05-4	CADLRNITNT-----SITTEG	GGEIKNC	22	
05-5	CADLRNTTNT-----SITTEG	GGEIKNC	22	
05-6	CADLRNTTNT-----SITTEG	GGEIKNC	22	
05-9	CADLRNTTNT-----SITTEG	GGEIKNC	22	
06-1	CTNLNTTDNNS-----NISSPTEG	GGEIKNC	25	
06-2	CTDWRNTDNTSGNNTNSTSGNSTDSAGGNISSPTEG	GGEIKNC	42	
06-4	CTNLNTTDNNS-----NISSPTEG	GGEIKNC	25	
08-1	CTDWKNTNNSNNNTS-----SNSNSTIGT	IEGGEIKNC	33	
08-2	CTDWKNTNNSNNSS-----NNSNSTIGT	IEGGEIKNC	33	
08-4	CTDWKPTNNSSSNSSNS---SSNSSSFNST	IEAGEIKNC	38	
08-6	CTDWKNTNNSSHNSS-----SNSNSTIGT	IEGGEIKNC	33	
08-7	CDDLRTTNT-----SITIER	GGEIKNC	22	
08-8	CTDWKPTNNSSSNSSNS---SSNSSSFNST	IERGEIKNC	38	
08-9	CTDWKNTNNSRNNSS-----SNSNSTIGT	IEGGEIKNC	33	
08-10	CTDWKPTNNSSSNSSS-----NSSSFNST	IERGEIKNC	34	
08-11	CTDWKNTNNSNNNTS-----SNSNSTIGT	IEGGEIKNC	33	
08-12	CTDYTNGNNTNNTSGSI----TNSTSDINST	IERGEIKNC	37	
08-13	CTDWKPTNNSSSNSSNS---SSNSSSFNST	IEAGEIKNC	38	

a.

	296		331	
HXB2	CTRPNNNTRKRIRIQRCPPGRAFVTIG-KTGNMROAHC	36		
05-8	CTRPNNNTRKSTIP--LGLGRAWYTTGQIIGDIROAHC	35		
05-3	CTRPNNNTRKSTIP--LGLGRAWYTTGQIIGDIROAHC	35		
05-4	CTRPNNNTRKSTIP--LGLGRAWYTTGQIIGDIROAHC	35		
05-5	CTRPNNNTRKSTIP--LGLGRAWYTTGQIIGDIROAHC	35		
05-6	CTRPNNNTRKSTIP--LGLGRAWYTTGQIIGDIROAHC	35		
05-9	CTRPNNNTRKSTIP--LGLGRAWYTTGQIIGDIROAHC	35		
06-1	CTRPNNNTRKSTIH--LGPGRWYATGEIIGNIROAHC	35		
06-2	CTRPNNNTRKSTIH--LGPGRWYATGEIIGNIROAHC	35		
06-4	CTRPNNNTRKSTIH--LGPGRWYATGEIIGNIROAHC	35		
08-1	CTRPSNNTRKRMT--LGPGRVWYTTGQIIGDIROAHC	35		
08-2	CTRPSNNTRKRMT--LGPGRVWYTTGQIIGDIROAHC	35		
08-4	CTRPGNNTRKRVT--LGPGRVWYTTGQIIGDIRKAYC	35		
08-6	CTRPSNNTRKRMT--LGPGRVWYTTGQIIGDIROAHC	35		
08-7	CTRPNNNTRKSTIS--LGLGRAWYTTGQIIGDIROAHC	35		
08-8	CTRPGNNTRKRIT--LGPGRVWYTTGQIIGDIRKAYC	35		
08-9	CTRPSNNTRKRMT--LGPGRVWYTTGQIIGDIROAHC	35		
08-10	CTRPGNNTRKRVT--LGPGRVWYTTGQIIGDIRKAYC	35		
08-11	CTRPSNNTRKRMT--LGPGRVWYTTGQIIGDIROAHC	35		
08-12	CTRPGNNTRKRVT--LGPGRVWYTTGQIIGDIRKAYC	35		
08-13	CTRPGNNTRKRVT--LGPGRVWYTTGQIIGDIRKAYC	35		

b.

HXB2 : MRVKE---KYQHLWRWGWRWGTMLLGLMLMICSATEKLWVTVYVGVVWKEATTTLFCASDAKAYDTEVHNWVATHACVPTDPNPQE
 CON515 : MRVTGIRRNYYQHLW----RWGKRLGLMLMICSAAENLWVTVYVGVVWKEATTTLFCASDAKAYDTEVHNWVATHACVPTDPNPQE
 CON437 : MRVMGIRKNYYQHLW----RWGTMGLMLMICSAAENLWVTVYVGVVWKEATTTLFCASDAKAYDTEVHNWVATHACVPTDPNPQE

131 V1 157

HXB2 : VVLVNVTENFNMWKNMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNS-----SSGRMIMEKGEIKNCSFNIST
 CON515 : VVLGNVTENFDMWKNMVEQMOEDVISLWDQSLKPCVKLTPLCVTLNCTDWKNTNNSNNSSNSNSIXSTIEGGEIKNCSFNITT
 CON437 : VRLKNVTENFNMWKNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTNYNNTSSN-----ASSTIEGEMKNCFSFNITT

V2 196

HXB2 : SIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNKTFNGTGPCNTVSTVQCTH
 CON515 : SICTKV-TDEALFYKLDIVPIDNDTTSYRLIXCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNKTFSGTGPCNTVSTVQCTH
 CON437 : SIKTKV-KDEALFYLDIVQIISNDSNSYRLINCNTSVITQACPKISFEPIPIHYCAPAGFGIICKNDKFKFNGTGPCNTVSTVQCTH

296 300 306 308 V3 316 319 322 331

HXB2 : GIRPVVSTQLLNGSLAEDEVIRSVNFTDNAKTIIVQLNTSVEINCTRPNNTTRKRIRIORGPGRFVTIG-KIGNMRQAHNCNIS
 CON515 : GIRPVVSTQLLNGSLAEDEVIRSSNFSNNAKVIIVELNESVEINCTRPNNTTRKRIT--LGPGRWYWTGQIIGDIRQAHNCNIS
 CON437 : GIRPVVSTQLLNGSLAEDEVIRSSNFSNNAKVIIVELNKSVVEINCTRPNNTTRKSH--LGPGRWYWTGQIIGDIRQAHNCNIS

385 389 397*398 V4 406 410*411 418

HXB2 : RAKWNNLTQKQIASKLREQFGNNTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSQLFNSTWFNSTWSTEGSNNTGSDTITLPCRI
 CON515 : RAKWNNLTRLITEKLREQFG-NKTIIFKQSSGGDPEIVMHSFNCGGEFFYCNTSLFNSTWNGNS--TWNDT-TSEDPTITLPCRI
 CON437 : RAKWNNLTRLITEKLREQFG-NKTIIFKQSSGGDPEIVMHSFNCGGEFFYCNTTLFNSTWNGNS--TWNSTSTENPTITLPCRI

460 V5 469

HXB2 : KQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGMDRDNWRSELYKYKVVKIEPLGVAPTAKARRVV
 CON515 : KQIVNMWQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGGNNTNGTETFRPGGGMDRDNWRSELYKYKVVKMEPLGVAPTAKARRVV
 CON437 : KQIVNMWQEVGKAMYAPPISGQIRCSSNITGLLLTRDGGNEINTTETFRPGGGMDRDNWRSELYKYKVVKIEPLGVAPTAKARRVV

511

HXB2 : QREKRAVGLGALFLGFLGAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIEAQHLLQLTVWGIKQLQARILAVERYLKDQQ
 CON515 : QREKRAVGMIGAMFLGFLGTAGSTMGAASLTTLTVQARQLLSGIVQQQNNLLRAIEAQHLLQLTVWGIKQLQARVLAVERYLKDQQ
 CON437 : QREKRAA--LGAMFLGFLGAGSTMGAASITLTVQARQLLSGIVQQQNNLLRAIEAQHLLQLTVWGIKQLQARVLAVERYLKDQQ

*611

HXB2 : LLGIWGC SGKLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLTHSLIEESQNQOEKNEELLELDKWASLWNWFDITK
 CON515 : LLGLWGC SGKLICTTAVPWNASWSNKSLEIWDNMTWMEWEREIDNYTREIYTLIEESQNQOEKNEELLELDKWASLWNWFDITK
 CON437 : LLGIWGC SGKLICTTAVPWNASWSNKSQSEIWDNMTWMEWEREINYTSTITTLIEKSNQOEKNEELLELDKWASLWNWFDITK

HXB2 : WLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVROGYSPLSEFOTHLPTPRGPDPRPEGIEEEGGERDRDRSIRLVNGSLALWDDLRLSL
 CON515 : WLWYIKLFIMIVGGLIGLRIVFAVLSIVNRVROGYSPLSLOTREPTORGPDPRPEGIEEEGGERDRDRSDRLVNGSLTLWEDLRNL
 CON437 : WLWYIKLFIMIVGGLVGLRIIFAVLSIVNRVROGYSPLSLOTREPAORGPDPRPEGIEEEGGERDRDRSERLVNGSLTLWEDLRNL

HXB2 : CLFSYHRLRDL LLIVTRIVELLGRRGWEALRYWNNLLQYWSQELKNASVSLNATAIAVAEGTDRVIEVQACRAIRNIPRRIQ
 CON515 : CLFSYHRLRDL LLIVIRIVELLGRRGWEALRYWNNLLQYWIQELKNASISLLNATAIAVAEGTDRVIEGQRAWAVLHPRRIQ
 CON437 : CLFSYHRLRDL LLIVARIVELLGRRGWEALRYWNNLLQYWIQELKNASISLLNATAIAVAEGTDRVIEVQACRAIRNIPRRIQ

HXB2 : GIERILL*
 CON515 : GIERILL*
 CON437 : GIERILL*